Logo

American Heart Association

  34
  0


Final ID: P3019

Role of liraglutide and other newer diabetic drugs in the improvement of the apnea-hypopnea index and sleepiness scale amongst OSA patients with standard care - a meta-analysis

Abstract Body: INTRODUCTION
Over 25 million Americans have obstructive sleep apnea (OSA), which has a prevalence of 26% and substantial DALYs owing to its relationship to chronic illnesses and morbidity. OSA may be treated with novel GLP-1 and GIP agonists that regulate obesity and metabolic function.

AIMS
The major goal of our research was to evaluate baseline and post-therapeutic apnea-hypopnea index (AHI) and Epworth Sleepiness Scale (ESS) in GLP-1 and GIP agonist patients (+/- CPAP) to routine care. We calculated weight loss benefits (mean BMI decrease and weight circumference change).

METHODS
PRISMA-compliant clinical trials were used for a systematic review and meta-analysis. We used MeSH keywords to find clinical trials on OSA outcomes with various GLP-1 and GIP analogues and standard treatment (CPAP) during the previous 10 years on PubMed, Ovid, Medline, and Clinicaltrials.gov. Non-clinical, non-English, non-full length, and non-human research were eliminated. We collected data on outcomes in Excel and translated baseline vs. post-intervention parameters into mean differences and standard deviations. Random effects models calculated weighted mean difference with 95% confidence interval and heterogeneity (I2) (α=0.05) to create forest plots highlighting the advantages of newer GLP-1/GIP analogs using RavMan 5.4.

RESULTS
Of 24 studies evaluated for outcomes, 8 were considered for quantitative analysis. We found GLP-1/GIP analogs (581 patients) were associated with a statistically significant reduction in AHI [-10.11 events per hour (-16.52 to -3.69), p=0.002, I2= 100%] compared to standard therapy (n=564). Meta-analysis of clinical trials (Idris et. and Blackman et al.) showed Exenatide and Liraglutide (n=182) were associated with a non-significant reduction of -2.61 [-7.87 to 2.65, p=0.33, I2= 89%] in ESS in compared with Placebo (n=179).

CONCLUSION
GLP-1/GIP agonists improve AHI and ESS reducing OSA severity in our meta-analysis. More clinical trials and prospective research should determine subgroup demographics, treatment classes, and dosages to assess the risk-benefit ratio and reduce OSA.
  • Parvataneni, Tarun  ( Aiken Regional Medical Center , Aiken , South Carolina , United States )
  • Patel, Urvish  ( Icahn School of Medi at Mount Sinai , New York , New York , United States )
  • Sandhu, Jujhar  ( Ampla Health , Yuba City , California , United States )
  • Mustaque, Tahsin  ( St John's Episcopal Hospital , Far Rockaway , New York , United States )
  • Shah, Shiv  ( , Auburn Hills , Michigan , United States )
  • Kim, San  ( Cleveland Clinic Foundation , Cleveland , Ohio , United States )
  • Shah, Nandan  ( Narendra Modi Medical College, L.G. Hospital Campus , Ahmedabad , Gujarat , India )
  • Salim, Yasin  ( All India Institute of Medical Sciences , Raipur , India )
  • Shah, Anuj  ( Smt NHL Medical College , Ahmedabad , India )
  • Vodapally, Mamatha  ( Adventist Health Family Medicine Residency , Hanford , California , United States )
  • Habib, Anam  ( Macon & Joan Brock Virginia Health Sciences, Eastern Virginia Medical School , Virginia Beach , Virginia , United States )
  • Kothari, Aditi  ( Texas Tech University Health Sciences Center El Paso , El Paso , Texas , United States )
  • Author Disclosures:
    Tarun Parvataneni: DO NOT have relevant financial relationships | Urvish Patel: DO NOT have relevant financial relationships | Jujhar Sandhu: No Answer | Tahsin Mustaque: No Answer | Shiv Shah: No Answer | San Kim: No Answer | Nandan Shah: No Answer | Yasin Salim: No Answer | Anuj Shah: No Answer | Mamatha Vodapally: No Answer | anam habib: No Answer | Aditi Kothari: DO NOT have relevant financial relationships
Meeting Info:
Session Info:

PS03.02 Cardiometabolic Health and Disorders 2

Saturday, 03/08/2025 , 05:00PM - 07:00PM

Poster Session

More abstracts on this topic:
More abstracts from these authors:
The Benefits of Probiotic Administration in Stroke Risk, Stroke-Related Gastrointestinal Complications, and Intestinal Flora Dysbiosis: A Meta-Meta-Analysis

Patel Urvish, Arumaithurai Kogulavadanan, Arora Rohan, Devabhaktuni Sarayu, Khan Aishah, Sudhir Gaurav, Gupta Devansh, Mukesh Sindu, Bhriguvanshi Arpita, Baskar Aakash, Parvataneni Tarun

Socio-Demographic Disparities in the Management Modalities of Pulmonary Embolism Amongst COVID-19 Patients: A Retrospective Population-Based Study

Patel Urvish, Savoiverekar Siddhi, Agarwal Ritu, Sajeev Malavika, Vyasa Jay, Parvataneni Tarun, Sakariya Dhrumil Chhaganbhai, Kondamuri Naga Sai Ragha Manpreet, Paredes Romero Enrique, Asif Kainat, Kalmani Vishal, Prasannakumary Rithi, Yerrababugari Mohammedafzal, Khinvasara Nidhi

You have to be authorized to contact abstract author. Please, Login
Not Available